GEN Exclusives

More »

GEN News Highlights

Back to Item »

Phase III Trial Finds Pfizer’s Axitinib Better than Sorafenib at Boosting PFS in Renal Cell Cancer

Axis 1032 study in previously treated advanced mRCC patients found axitinib increased PFS to 6.7 months.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »